While Ozempic maker Novo Nordisk has fallen on tough times, Wall Street analysts have still been reluctant to advise ...
Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still ...
Novo Nordisk raised its full-year outlook late Tuesday as it reported a better-than-expected quarter. Investors remained focused on pricing pressure, the quality of the earnings beat, and whether the ...
Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish drugmaker Novo Nordisk said Wednesday that it will drop prices 23% for all doses of ...
1mon
Novo Nordisk, the pharma giant behind Ozempic and Wegovy, has surprising love story origins. The founders, a married couple, ...
Citi has reiterated its 'sell' rating on Novo Nordisk (NYSE:NVO), the Danish pharmaceutical group, with a price target of 265 ...
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027. Table with 4 columns and 15 rows.
Novo Nordisk rolls out oral Wegovy in Germany, first EU market, as investors await strategy update on Sept 21 amid mixed ...
Costco members can now buy popular weight-loss and diabetes drugs Ozempic and Wegovy at a discounted price. Novo Nordisk, the maker of the GLP-1 medications, announced a partnership with the retailer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results